Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1557746/000155837018005179/f8-k.htm
January 2023
January 2023
December 2022
November 2022
November 2022
August 2022
August 2022
June 2022
May 2022
April 2022
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1557746/000155837018005179/f8-k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aclaris Therapeutics, Inc..
Aclaris Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Ticker: ACRSEvents:
CIK: 1557746
Form Type: 8-K Corporate News
Accession Number: 0001558370-18-005179
Submitted to the SEC: Fri Jun 08 2018 7:22:20 AM EST
Accepted by the SEC: Fri Jun 08 2018
Period: Thursday, June 7, 2018
Industry: Pharmaceutical Preparations